Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2004-01-14
2009-08-25
Parkin, Jeffrey S. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S208100
Reexamination Certificate
active
07579143
ABSTRACT:
This invention relates to methods for assessing the effectiveness of non-nucleoside reverse transcriptase inhibitor on an HIV that rely on detection of combinations of mutations in HIV reverse transcriptase associated with altered susceptibility to such compounds. In some embodiments, the combinations of mutations include various combinations of mutations at codons 190, 101, 130, and 98 of HIV reverse transcriptase.
REFERENCES:
patent: 5436131 (1995-07-01), Condra et al.
patent: 5631128 (1997-05-01), Kozal et al.
patent: 5650268 (1997-07-01), Kozal et al.
patent: 5837464 (1998-11-01), Capon et al.
patent: 5917033 (1999-06-01), Modak et al.
patent: 6033902 (2000-03-01), Haseltine et al.
patent: 6103462 (2000-08-01), Paulous et al.
patent: 6124327 (2000-09-01), Silverman et al.
patent: 6242187 (2001-06-01), Capon et al.
patent: 6653081 (2003-11-01), Whitcomb
patent: 2004/0067487 (2004-04-01), Whitcomb
patent: 99925874 (2004-09-01), None
patent: 99933581 (2004-09-01), None
patent: 0194452 (2004-10-01), None
patent: WO97/27319 (1997-07-01), None
patent: WO97/27332 (1997-07-01), None
patent: PCT/US99/14486 (1999-06-01), None
patent: WO99/67427 (1999-06-01), None
patent: PCT/US99/11629 (1999-09-01), None
patent: WO99/61658 (1999-12-01), None
patent: WO02/22781 (2001-09-01), None
patent: PCT/US01/18882 (2001-10-01), None
patent: PCT/US01/28736 (2002-05-01), None
patent: PCT/US03/21024 (2004-05-01), None
Fujiwara, T., et al., 1998, S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1, Antimicrob. Agents Chemother. 42(6):1340-1345.
Fujiwara, T., et al., 1998, “S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1”, Antimicrob. Agents Chemother. 42(6): 1340-1345.
Bacheler, L, et al., 2001, “Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy”, J. Virol. 75(11):4999-5008.
Ceccherini-Silberstein, F., et al., 2007, “Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors”, J. Virol. 81(20):11507-11519.
Ahluwalia, G. S., et al. (1996) “2′, 3′-Didehydro-31-deoxythymidine: Regulation of its Metabolic Activation by Modulators of Thymidine-5′-triphosphate Biosynthesis”Mol. Pharm.50: 160-165.
Appelt, et al., (1991) “Design of Enzyme Inhibitors Using Iterative Protein Crystallographic Analysis,” J. Med. Chem. 34: 1925-1934.
Arnold E., et al. (1995) “Structures of DNA and RNA Polymerases and Their Interactions with Nucleic Acid Substrates”,Curr Opin Struct Biol5:27-38.
Back, KT, et al, (1996) “Reduce Replication of 3TC-Resistant HIV-1 Variants in Primary Cells Due to a Processivity Defect of the Reverse Transcriptase Enzyme”,EMBO15: 4040-4049.
Balzarini J, (1998) “A Novel Mutation (F227L) Arises in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 on Dose-Escalating Treatment of HIV Type 1-Infected Cell Cultures With the Nonnucleoside Reverse Transcriptase Inhibitor Thiocarboxanilide UC-781”AIDS Res. Human, 14(3):255-260.
Balzarini J, et al. (1997) “Zidovudine-Resistant Human Presence Immunodeficiency Virus Type 1 Strains Subcultured in the of Both Lamivudine and Quinoxaline HBY 097 Retain Marked Sensitivity to HBY 097 but not to Lamivudine”J of Infect Dis, 176:1392-1397.
Balzarini J., et al., (1992) “HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity Against HIV1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase”, Virology 192:246-253.
Barnes WM, (1994) “PCR Amplification of up to 35-kb DNA with High Fidelity and High Yield from I. Bacteriophage Templates”PNAS91:2216-2220.
Bartenschlager R, et al, (1994) “Kinetic and Structural Analyses of Hepatitis C Virus Polyprotein Processing”, J.Virol.68:5045-5055.
Boucher Cab, et al, (1993) “High-Level Resistance to (−) Enantiomeric 2′-Deoxy-3′-Thiacytidine In Vitro is Due to One Amino Acid Substitution in the Catalytic Site of Human Immunodeficiency Virus Type 1 Reverse Transcriptase”, Antimicrob Agents Chemother, 37:2231-2234.
Boucher Cab, et al, (1990) “Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy”, Lancet 336:585-590.
Boyer, et al., “Analysis of Nonnucleoside Drug-Resistant Variants of Human Immunodeficiency Virus Type 1 Reverse Transcriptase,” J. Virol., 67(4):2412-2420 (1993).
Cheeseman S.H., et al. (1995) “Phase I/II Evaluation of Defic Nevirapine Alone and in Combination with Zidvudine for Infection with Human Immunodeficiency Virus”,J Acquir Immune Syndr8:141-151.
Coffin JM, (1995) “HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy”, Science 267:483-489.
Craig C and Moyle G, (1997) “The development of resistance of HIV-1 to zalcitabine”, AIDS 11:271-279.
Croteau G. et al (1997) “Impaired Fitness of Human Immunodeficiency Virus Type 1 Variants with High-Level Resistance to Protease Inhibitors” JVirol71:1089-1096.
D'Aquilla R.T. (1994) “Molecular Pathogenesis and Laboratory Monitoring”,Clin Lab Med14:393-423.
De Clercq E, (1997) “Development of Resistance of Human the 4); Immunodeficiency Virus (HIV) to Anti-HIV Agents: How to Prevent Problem”Intnl of Antimicro Agnts, 9:21-36.
De Clerq E, (1992) “HIV Inhibitors Targeted at the Reverse Transcriptase”, AIDS Res.HumRetrovin.8:119-134.
DeJong, M.D., et al. (1994) “Alternating Nevirapine and Infected Zidovudine Treatment of Human Immunodeficiency Virus Type 1Persons Does Not Prolong Nevirapine Activity”,J Infect Dis169:1346-1350.
DeJong MD, et al, (1996) “Host-parasite Dynamics and Outgrowth of Virus Containing a Single K7OR Amino Acid Change in Reverse Transcriptase are Responsible for the Loss of Human Immunodeficiency Virus Type 1 RNA Load Suppression by Zidovudine”, PNAS 93:5501-5506.
Descamps, et al., 1997 “Susceptibility of Human Immunodeficiency Virus Type 1 Group O Isolates to Antiretroviral Agents: In Vitro Phenotype and Genotypic Analysis,” J. of Virology 71(11): 8893-98.
De Antoni A., et al. Mutations in a pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.J. Infect Dis.Oct. 1997; 176(4): 899-903.
Doyon L, et al, (1996) “Second Locus Involved in Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors”,J Virol70:3763-3769.
Dueweke, T.J., et al. (1993) “A Mutation in Reverse to Other Transcriptase of Bis (Heteroaryl) Piperzine Resistant Human Immunodeficiency Virus Type 1. That Confers Increased Sensitivity; Nonnucleoside Inhibitors”,PNAS90:4713-4717.
Eastman, P. Scott, et al. (1995) Monisotopic Hybridization Assay for Determination of Relative Amounts of Genotypic HumanMicro, Immunodeficiency Virus Type 1 Zidovudine Resistance,J Clin2777-2780.
Fitzgibbon et al. Human Immunodeficiency virus type 1 pol gene mutations in an AIDS pateint treated with multiple antiretroviral drugs. Journal of Virology, vol. 67, No. 12 (1993) pp. 7271-7275.
Frenkel et al. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. Journal of Clinical Immunology. vol. 33, No. 2 (1995) pp. 342-347.
Frost, S.D.W., and McLean, A.R. (1994) “Quasispecies Dynamics and the Emergence of Drug Resistance During Zidovudine Therapy of Hiv Infection”,AIDS8:323-332.
Gerondelis P, et al, (1999) “The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant is Replication Defective and Demonstrates Alternat
Jones Day
Monogram Biosciences, Inc.
Parkin Jeffrey S.
LandOfFree
Method of assessing the effectiveness of a non-nucleoside... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of assessing the effectiveness of a non-nucleoside..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of assessing the effectiveness of a non-nucleoside... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4092411